MA46337A - Composé de pyridine - Google Patents

Composé de pyridine

Info

Publication number
MA46337A
MA46337A MA046337A MA46337A MA46337A MA 46337 A MA46337 A MA 46337A MA 046337 A MA046337 A MA 046337A MA 46337 A MA46337 A MA 46337A MA 46337 A MA46337 A MA 46337A
Authority
MA
Morocco
Prior art keywords
pyridine compound
pharmaceutically acceptable
acceptable salt
relates
compound
Prior art date
Application number
MA046337A
Other languages
English (en)
Other versions
MA46337B1 (fr
Inventor
Hiroaki Inagaki
Hideaki Kageji
Yasuyuki Kaneta
Kiyoshi Nakayama
Hidenori Namiki
Yoshihiro Shibata
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MA46337A publication Critical patent/MA46337A/fr
Publication of MA46337B1 publication Critical patent/MA46337B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne un composé ayant une action inhibitrice de la kinase ret ou un sel pharmaceutiquement acceptable de celui-ci, utile dans le traitement de maladies telles que le cancer. En particulier, l'invention concerne un composé représenté par la formule générale (i) suivante telle que définie dans la description : (i) ou un sel pharmaceutiquement acceptable de celui-ci.
MA46337A 2016-09-29 2017-09-28 Composé de pyridine MA46337B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (fr) 2016-09-29 2017-09-28 Composé de pyridine

Publications (2)

Publication Number Publication Date
MA46337A true MA46337A (fr) 2019-08-07
MA46337B1 MA46337B1 (fr) 2021-04-30

Family

ID=60020249

Family Applications (2)

Application Number Title Priority Date Filing Date
MA46337A MA46337B1 (fr) 2016-09-29 2017-09-28 Composé de pyridine
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé

Country Status (33)

Country Link
US (2) US10851092B2 (fr)
EP (2) EP3519398B1 (fr)
JP (2) JP2018052878A (fr)
KR (1) KR102520543B1 (fr)
CN (2) CN110036007B (fr)
AU (2) AU2017335242C1 (fr)
BR (1) BR112019006047A2 (fr)
CA (1) CA3035860A1 (fr)
CL (1) CL2019000844A1 (fr)
CO (1) CO2019004034A2 (fr)
CY (1) CY1123988T1 (fr)
DK (1) DK3519398T3 (fr)
EA (1) EA037103B1 (fr)
EC (1) ECSP19030134A (fr)
ES (1) ES2868748T3 (fr)
HR (1) HRP20210447T1 (fr)
HU (1) HUE054824T2 (fr)
IL (1) IL265630B (fr)
LT (1) LT3519398T (fr)
MA (2) MA46337B1 (fr)
MD (1) MD3519398T2 (fr)
MX (1) MX2019003747A (fr)
PE (1) PE20190805A1 (fr)
PH (1) PH12019500480A1 (fr)
PL (1) PL3519398T3 (fr)
PT (1) PT3519398T (fr)
RS (1) RS61640B1 (fr)
SG (1) SG11201901937WA (fr)
SI (1) SI3519398T1 (fr)
SM (1) SMT202100315T1 (fr)
UA (1) UA123964C2 (fr)
WO (1) WO2018060714A1 (fr)
ZA (1) ZA201902232B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3371171B1 (fr) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibiteurs de ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
WO2019143977A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrrolo[2,3-d]pyrimidines substitués utilisés en tant qu'inhibiteurs de la kinase ret
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
BR112020020273A2 (pt) 2018-04-03 2021-04-06 Blueprint Medicines Corporation Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (fr) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methodes pour le traitement de cancers qui ont acquis une resistance aux inhibiteurs de kinase
US20230019999A1 (en) * 2019-11-18 2023-01-19 Chugai Seiyaku Kabushiki Kaisha Combination drug
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2021164741A1 (fr) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 Composé de bisamide de phényle
CN117903123A (zh) * 2020-02-20 2024-04-19 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
EP4157829A1 (fr) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Formes solide de pralsetinib
WO2022238706A1 (fr) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Inhibiteur de ret pour le traitement du cancer médullaire de la thyroïde à altération de ret ou du cancer du poumon non à petites cellules à altération de ret
CA3234317A1 (fr) 2021-10-22 2023-12-14 Wa Xian Methodes et compositions pour traiter une lesion inflammatoire chronique, une metaplasie, une dysplasie et des cancers des tissus epitheliaux
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
EP1670787B1 (fr) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Inhibiteurs des cytokines
JP2009528335A (ja) 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キナゾリン誘導体
EP1994024A2 (fr) 2006-03-02 2008-11-26 AstraZeneca AB Dérivés de la quinoline
WO2007113565A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de la naphtyridine comme agents anti-cancéreux
WO2007113548A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de naphtyridine
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
PL2404908T3 (pl) * 2009-02-27 2014-12-31 Teijin Ltd Sposób wytwarzania podstawionej fenylem pochodnej heterocyklicznej przez sprzężenie z użyciem katalizatora metalu przejściowego
BR112012003661A2 (pt) 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
CN102573832B (zh) * 2009-08-25 2015-07-22 阿布拉科斯生物科学有限公司 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗
CA2798209A1 (fr) 2010-04-23 2011-10-27 Kineta, Inc. Composes antiviraux
EP2651930B1 (fr) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Inhibiteurs biarylamide de production de leukotriènes
WO2014012050A2 (fr) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Composés utilisables en vue du traitement de l'amyotrophie spinale
AU2014229233B2 (en) 2013-03-15 2016-08-11 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors
EP3039021A1 (fr) * 2013-08-30 2016-07-06 Ambit Biosciences Corporation Composés de biaryle acétamide et procédés d'utilisation de ceux-ci
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US9783522B2 (en) * 2014-04-24 2017-10-10 Mitsubishi Tanabe Pharma Corporation 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
RS58813B1 (sr) * 2014-09-10 2019-07-31 Glaxosmithkline Ip Dev Ltd Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret)
MX381233B (es) * 2014-09-10 2025-03-12 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret).
CA2964113A1 (fr) 2014-10-14 2016-04-21 La Jolla Institute Of Allergy & Immunology Inhibiteurs de la proteine tyrosine phosphatase de faible poids moleculaire et utilisations
CN104844589B (zh) * 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
WO2016127074A1 (fr) * 2015-02-06 2016-08-11 Blueprint Medicines Corporation Utilisation de dérivés 2-(pyridine-3-yl)-pyrimidine en tant qu'inhibiteurs de ret
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
US10851092B2 (en) 2020-12-01
MX2019003747A (es) 2019-09-19
JP2019534871A (ja) 2019-12-05
ES2868748T3 (es) 2021-10-21
PT3519398T (pt) 2021-03-24
CA3035860A1 (fr) 2018-04-05
IL265630B (en) 2021-10-31
PH12019500480A1 (en) 2019-08-05
RS61640B1 (sr) 2021-04-29
JP7098609B2 (ja) 2022-07-11
PL3519398T3 (pl) 2021-06-28
EP3519398A1 (fr) 2019-08-07
SI3519398T1 (sl) 2021-07-30
CN113788824A (zh) 2021-12-14
EA201990833A1 (ru) 2019-10-31
CN110036007A (zh) 2019-07-19
CO2019004034A2 (es) 2019-07-10
UA123964C2 (uk) 2021-06-30
AU2021261899A1 (en) 2021-12-02
JP2018052878A (ja) 2018-04-05
HRP20210447T1 (hr) 2021-07-23
HUE054824T2 (hu) 2021-10-28
LT3519398T (lt) 2021-05-10
PE20190805A1 (es) 2019-06-10
EA037103B1 (ru) 2021-02-05
SG11201901937WA (en) 2019-04-29
CL2019000844A1 (es) 2019-06-07
IL265630A (en) 2019-05-30
ZA201902232B (en) 2022-12-21
US20200039974A1 (en) 2020-02-06
AU2017335242A1 (en) 2019-05-02
BR112019006047A2 (pt) 2019-06-25
AU2017335242C1 (en) 2021-12-09
MD3519398T2 (ro) 2021-05-31
EP3519398B1 (fr) 2021-02-24
SMT202100315T1 (it) 2021-07-12
KR20190086442A (ko) 2019-07-22
AU2017335242B2 (en) 2021-08-19
ECSP19030134A (es) 2019-08-30
EP3828178A1 (fr) 2021-06-02
DK3519398T3 (da) 2021-03-29
US20210163464A1 (en) 2021-06-03
MA54910A (fr) 2022-04-13
MA46337B1 (fr) 2021-04-30
KR102520543B1 (ko) 2023-04-10
CY1123988T1 (el) 2022-05-27
WO2018060714A1 (fr) 2018-04-05
CN110036007B (zh) 2021-10-15

Similar Documents

Publication Publication Date Title
MA46337B1 (fr) Composé de pyridine
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
MA52948B1 (fr) Composés
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
EA201890473A1 (ru) Гетероарильные производные в качестве ингибиторов parp
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MA38454B1 (fr) Inhibiteurs de protéines kinases
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
MX391812B (es) Agonista fxr derivado de esteroides.
EA202193015A1 (ru) Ингибиторы cdk
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX373786B (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer.
EA201991884A2 (ru) Ингибиторы g12c kras
MD4659B1 (ro) Polimorf al inhibitorilor SYK
EA201792478A1 (ru) Соединения-ингибиторы передачи сигналов пути notch
MA39983B1 (fr) Dérivés de carboxamide
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
NZ746906A (en) Oxaborole esters and uses thereof
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2021007258A (es) Composiciones de esparsentan amorfas.
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain